Safety and Performance of a New Coating for Urinary Intermittent Catheters
Launched by COLOPLAST A/S · Feb 26, 2013
Trial Information
Current as of July 22, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Have given written informed consent and signed letter of authority
- • 2. Be at least 18 years of age and have full legal capacity
- • 3. Be a male
- • 4. Willing to refrain from using analgetics up to 24 hours prior to catheterization visits
- Exclusion Criteria:
- • 1. Abnormalities, diseases or surgical procedures performed in the lower urinary tract
- • 2. Symptoms of urinary tract infections (at least one of the following: frequent urination, stinging or pain at urination)
- • 3. Participating in other interventional clinical investigations during this investigation (inclusion to termination) or have previously participated in this investigation (including run-in period)
- • 4. Known hypersensitivity toward any of the test products -
About Coloplast A/S
Coloplast A/S is a leading global medical device company headquartered in Denmark, specializing in products and services for individuals with intimate healthcare needs. With a strong commitment to innovation, Coloplast develops solutions in areas such as ostomy care, urology, and wound care. The company prioritizes patient-centered design, combining advanced technology with user-friendly applications to enhance quality of life for patients. Coloplast A/S actively conducts clinical trials to validate the safety and efficacy of its products, ensuring they meet the highest standards of care and contribute to improved health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Copenhagen, , Denmark
Patients applied
Trial Officials
Per Bagi, MD, PhD
Principal Investigator
Department of Urology, Rigshospitalet Denmark
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials